An observational study in Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome and Opiate Addiction, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-27.
Sponsored by Yale University · Observational
STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.
STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.
2,040 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 272 are open to participants now.
This study's enrollment of 159 is below the median of 236 across 355 observational studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.
Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC.
Exclusion Criteria:
Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
Drug: buprenorphine
No buprenorphine
To provide buprenorphine for 12 months for those who are interested in receiving it.
Also known as: Suboxone
VL <400
Blood test for HIV viral load
Time frame: Month 0
CD4+ cell count
Blood test for HIV CD4+ cell count
Time frame: Month 0
VL <400
Blood test for HIV viral load
Time frame: 6 months
CD4+ cell count
Blood test for HIV CD4+ cell count
Time frame: 6 months
VL <400
Blood test for HIV viral load
Time frame: 12 months
CD4+ cell count
Blood test for HIV CD4+ cell count
Time frame: 12 months
HIV risk behaviors
Survey for HIV risks
Time frame: Month 0
HIV risk behaviors
Survey for HIV risks
Time frame: 6 months
HIV risk behaviors
Survey for HIV risks
Time frame: 12 months
Retention in HIV care
Survey data for retention
Time frame: Month 0
Retention in HIV care
Survey data for retention
Time frame: 6 months
Retention in HIV care
Survey data for retention
Time frame: 12 months
Opioid use
Measure of relapse to opioid use
Time frame: Month 0
Opioid use
Measure of relapse to opioid use
Time frame: 6 months
Opioid use
Measure of relapse to opioid use
Time frame: 12 months
Medically assisted therapy retention
Measure of length of time on Methadone or Buprenorphine
Time frame: Month 0
Medically assisted therapy retention
Measure of length of time on Methadone or Buprenorphine
Time frame: 6 months
Medically assisted therapy retention
Measure of length of time on Methadone or Buprenorphine
Time frame: 12 months
Reincarceration
Measure of rearrest and reincarceration
Time frame: Month 0
Reincarceration
Measure of rearrest and reincarceration
Time frame: 6 months
Reincarceration
Measure of rearrest and reincarceration
Time frame: 12 months
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome→
Yale University